Zobrazeno 81 - 90
of 3 712
pro vyhledávání: ''
Autor:
Diego Balboa, Zoltán Wiener, Kari Alitalo, Pauliina Kallio, Veli-Matti Leppänen, Jenny Högström, Marianne Lähde, Sarika Heino
Publikováno v:
Cancer Research. 78:5820-5832
The homeobox transcription factor PROX1 is induced by high Wnt/β-catenin activity in intestinal adenomas and colorectal cancer, where it promotes tumor progression. Here we report that in LGR5+ colorectal cancer cells, PROX1 suppresses the Notch pat
Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Autor:
Kendra S. Carmon, Na Zhang, Hua Ren, Mingyao Liu, Qingyun Liu, Min Qian, Stefan Siwko, Bing Du, Jie Zhang, Binghe Tan, Juliang Qin, Honghui Han, Xiujuan Shi
Publikováno v:
Cancer Research. 78:4929-4942
Therapies targeting immune checkpoints have shown great clinical potential in a subset of patients with cancer but may be hampered by a failure to reverse the immunosuppressive tumor microenvironment (TME). As the most abundant immune cells in TME, t
Publikováno v:
Cancer research. 81(18)
Tumor suppressors represent a critical line of defense against tumorigenesis. Their mechanisms of action and the pathways they are involved in provide important insights into cancer progression, vulnerabilities, and treatment options. Although nuclea
Autor:
Arezki Chekaoui, Hildegund C.J. Ertl
Publikováno v:
Cancer research. 81(17)
Reducing metabolic stress within the tumor microenvironment (TME) could be essential for improving the efficacy of cancer immunotherapy. Using a mouse model of melanoma, we show here that appropriately timed treatment with the PPARα agonist fenofibr
Autor:
Wenwei Hu, Zhaohui Feng
Publikováno v:
Cancer Research. 81:3762-3763
The tumor suppressor p53 gene is mutated in approximately 50% of all human tumors. Many tumor-associated mutant p53 proteins misfold into a common, denatured conformation and accumulate to high levels in human tumors. In such tumors, these mutant for
Publikováno v:
Cancer Research. 81:3158-3159
Radiotherapy plays an important role in the management of pancreatic ductal adenocarcinoma (PDAC), especially when patients are not surgical candidates. Radiation-induced tumor death provokes an acute inflammation followed by a late-fibrotic response
Autor:
Cheryl Meguid, Miles Piper, James C. Costello, Michael J. Gough, Adam C. Mueller, Michael W. Knitz, Shilpa Bhatia, Adrie van Bokhoven, Kimberly R. Jordan, Antonio Galvao Neto, Richard D. Schulick, S.J. Zakem, Benjamin Van Court, Jason S. Williams, Martin D. McCarter, Thomas E. Bickett, Marco Del Chiaro, Kirk C. Hansen, Casey S. Greene, Brisa Peña, Shiv Bhuvane, Sana D. Karam, David Lagares, Ayman Oweida, Luisa Mestroni, Kathryn L. Zolman, Wells A. Messersmith, Peter J. Dempsey, Andrew Goodspeed, M. Scott Lucia, Matthew R.G. Taylor, Jacob Gadwa, Laurel B. Darragh, Karyn A. Goodman, Andy Phan
Publikováno v:
Cancer Res
Stromal fibrosis activates prosurvival and proepithelial-to-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma (PDAC). In patient tumors treated with neoadjuvant stereotactic body radiation therapy (SBRT), we found upregulation
Autor:
Geoffrey Neale, Sarang Tartey, Thirumala-Devi Kanneganti, Peter Vogel, R. K. Subbarao Malireddi
Publikováno v:
Cancer research. 81(9)
Macrophages are critical mediators of tissue homeostasis, cell proliferation, and tumor metastasis. Tumor-associated macrophages (TAM) are generally associated with tumor-promoting immunosuppressive functions in solid tumors. Here, we examined the tr
Autor:
Puay Hoon Tan, Neha Rohatgi, Umesh Ghoshdastider, Joe Poh Sheng Yeong, Anders Jacobsen Skanderup, Ramanuj DasGupta, Sundar Solai, Tin Trung Nguyen, Balram Chowbay, Yu Amanda Guo, Angeline M.L. Wong, Jabed Iqbal, Egor Revkov, Probhonjon Baruah, Simone Rizzetto, Marjan Mojtabavi Naeini
Publikováno v:
Cancer research. 81(7)
Signaling between cancer and nonmalignant (stromal) cells in the tumor microenvironment (TME) is a key to tumor progression. Here, we deconvoluted bulk tumor transcriptomes to infer cross-talk between ligands and receptors on cancer and stromal cells
Autor:
Marwa Zerhouni, Rachid Benhida, Issam Ben-Sahra, Emilie Jaune, Vincent S. Gutierrez, Thomas Cluzeau, Patricia Abbe, Thierry Passeron, Meri K. Tulic, Arnaud Jacquel, Stéphane Rocchi, Patrice Dubreuil, Brendan P. O’Hara, Hella Amdouni, Frederic Luciano, Guillaume Robert, Anthony Martin, Nathan Furstoss, Patrick Auberger, Guillaume E. Beranger, Mohsine Driowya, Nedra Tekaya, Claire Regazzetti
Publikováno v:
Cancer research. 81(14)
Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic